rs61755781
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The ENST00000230381.7(PRPH2):āc.422A>Gā(p.Tyr141Cys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,894 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Y141D) has been classified as Likely pathogenic.
Frequency
Consequence
ENST00000230381.7 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PRPH2 | NM_000322.5 | c.422A>G | p.Tyr141Cys | missense_variant | 1/3 | ENST00000230381.7 | NP_000313.2 | |
PRPH2 | XR_007059288.1 | n.685A>G | non_coding_transcript_exon_variant | 1/3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PRPH2 | ENST00000230381.7 | c.422A>G | p.Tyr141Cys | missense_variant | 1/3 | 1 | NM_000322.5 | ENSP00000230381 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461894Hom.: 0 Cov.: 32 AF XY: 0.00000138 AC XY: 1AN XY: 727248
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:3Other:1
not provided, no classification provided | literature only | Retina International | - | - - |
Pathogenic, no assertion criteria provided | curation | Leiden Open Variation Database | Jun 25, 2021 | Curator: Global Variome, with Curator vacancy. Submitters to LOVD: Julia Lopez, LOVD, Manon Peeters. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 18, 2020 | Published functional studies demonstrate a damaging effect (alteration of PRPH2 protein complex formation) (Stuck et al., 2014); Not observed in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 32531846, 28559085, 29961824, 28053051, 15370544, 12882809, 11139241, 25082885, 25097241, 22466463, 25001182) - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | May 22, 2017 | - - |
Retinal dystrophy Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, Univ. Regensburg, Univ. Regensburg | Jan 01, 2009 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Blueprint Genetics | Jul 31, 2019 | - - |
Vitelliform macular dystrophy 3 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 01, 2014 | - - |
Patterned dystrophy of the retinal pigment epithelium Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | NEI Ophthalmic Genomics Laboratory, National Institutes of Health | Jan 07, 2020 | The variant NM_000322.4:c.422A>G in the PRPH2 gene has been previously studied (PMIDs 11139241, 15370544, 22466463, 25082885, 25001182, 25097241, 28559085). We found this variant in 14 patient(s) in a PRPH2 cohort study (Reeves et al. 2020). This variant is listed in dbSNP and/or HGMD (rs61755781,CM010125). It is absent in gnomAD browser. It is enriched in the PRPH2 disease cohort. We invoked ACMG criteria [PS3, PS4, PM1, PM2, PP3, PP5, PP1-S] and classified NM_000322.4:c.422A>G in the PRPH2 gene as a Pathogenic mutation. - |
Patterned macular dystrophy 1 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 01, 2014 | - - |
Cone-rod dystrophy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | NEI Ophthalmic Genomics Laboratory, National Institutes of Health | Jan 07, 2020 | The variant NM_000322.4:c.422A>G in the PRPH2 gene has been previously studied (PMIDs 11139241, 15370544, 22466463, 25082885, 25001182, 25097241, 28559085). We found this variant in 14 patient(s) in a PRPH2 cohort study (Reeves et al. 2020). This variant is listed in dbSNP and/or HGMD (rs61755781,CM010125). It is absent in gnomAD browser. It is enriched in the PRPH2 disease cohort. We invoked ACMG criteria [PS3, PS4, PM1, PM2, PP3, PP5, PP1-S] and classified NM_000322.4:c.422A>G in the PRPH2 gene as a Pathogenic mutation. - |
Autosomal recessive bestrophinopathy Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Molecular Genetics, University of Zurich | Jan 30, 2021 | - - |
PRPH2-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 19, 2024 | This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 141 of the PRPH2 protein (p.Tyr141Cys). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with autosomal dominant retinitis pigmentosa or pattern dystrophy (PMID: 16113362, 16799052, 25082885, 25097241). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 98666). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PRPH2 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects PRPH2 function (PMID: 25001182). For these reasons, this variant has been classified as Pathogenic. - |
Stargardt disease Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | NEI Ophthalmic Genomics Laboratory, National Institutes of Health | Jan 07, 2020 | The variant NM_000322.4:c.422A>G in the PRPH2 gene has been previously studied (PMIDs 11139241,15370544, 22466463, 25082885, 25001182, 25097241, 28559085). We found this variant in 14 patient(s) in a PRPH2 cohort study (Reeves et al. 2020). This variant is listed in dbSNP and/or HGMD (rs61755781,CM010125). It is absent in gnomAD browser. It is enriched in the PRPH2 disease cohort. We invoked ACMG criteria [PS3, PS4, PM1, PM2, PP3, PP5, PP1-S] and classified NM_000322.4:c.422A>G in the PRPH2 gene as a Pathogenic mutation. - |
Retinitis pigmentosa Pathogenic:1
Pathogenic, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Apr 01, 2021 | The p.Tyr141Cys variant in PRPH2 was identified in an individual with Retinitis pigmentosa, via a collaborative study between the Broad Institute's Center for Mendelian Genomics and the Pierce lab (https://oculargenomics.meei.harvard.edu/labs/pierce-lab/lab-members/). Through a review of available evidence we were able to apply the following criteria: PM2, PP3, PS3, PP1, PS4. Based on this evidence we have classified this variant as Pathogenic. If you have any questions about the classification please reach out to the Pierce Lab. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at